Study of Pegvaliase use in pregnancy and breastfeeding for PKU
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at how taking Pegvaliase during pregnancy and breastfeeding affects pregnancy, baby health, and early infant outcomes in people with PKU. It may help improve care guidance for patients and babies exposed to Pegvaliase before birth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or a legally authorized representative) can sign consent for the study.
- You are currently pregnant, or you have pregnancy timing that the study can classify as prospective or retrospective based on prior prenatal testing.
- You have been diagnosed with PKU (phenylketonuria) based on standard care in your area.
- You were treated with Pegvaliase at any time starting at least 2 weeks before your last menstrual period (LMP).
- You agree the study team can contact your doctors (and your baby’s doctor) to collect medical information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the long-term safety of Palynziq (pegvaliase) in people with PKU as they take the medicine over time. It may help you and other patients understand long-term side effects and whether Palynziq stays safe.
This long-term study checks how the immune system reacts to Palynziq (a treatment for PKU) over time. It involves extra blood tests for people already in another PKU study called 165-501.
This study tests whether combining a drug called methotrexate with Palynziq (a treatment for PKU) can help control immune responses and improve treatment outcomes. It may be an option for adults with PKU who have never used Palynziq or who have not reached target blood levels after at least 24 weeks.
This study looks at how educational, social support, and nutrition help affect pregnancy outcomes and quality of life in women with PKU. It may help you better manage PKU-related needs before and during pregnancy.
This study tests a new injection called GS1168 for adults with phenylketonuria (PKU) whose current treatments are not working well. The goal is to see if it can help control their PKU better.
This trial tests an investigational drug (AG-181) for people with PKU who have a specific genetic change (R408W mutation). It aims to check if the drug is safe and how it works in your body.
Hear when a new Phenylketonuria, Maternal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.